Proposed monographs for omission from the BP 2027

Published 23 January 2026

The British Pharmacopoeia Commission is continuing to ensure that the publication remains relevant and comprehensive. As part of this work, several monographs included in the current edition of the British Pharmacopoeia have been proposed for omission due to the lack of UK based Marketing Authorisation Holders and/or low usage within the UK. 

The monographs proposed for omission from the BP 2027 are:

  • Diphenylpyraline Hydrochloride

  • Pentazocine Injection

  • Piperazine Phosphate Chewable Tablets

  • Piperazine Phosphate Tablets

  • Etodolac Capsules

  • Ephedrine Nasal Drops

  • Flurbiprofen Eye Drops

  • Flurbiprofen Suppositories

  • Lidocaine Sterile Solution

  • Moxisylyte Hydrochloride

  • Moxisylyte Tablets

  • Prochlorperazine Oral Solution

  • Nystatin Ointment

  • Pancuronium bromide Injection

  • Iron Sucrose Injection

  • Cyanocobalamin oral solution

  • Codeine Phosphate Injection

The British Pharmacopoeia is used in many countries and we welcome feedback from national and international stakeholders regarding the proposed omissions. Monographs omitted from the BP 2027 publications will remain available within the BP Archive, which is accessible via the BP Online publication. Such monographs continue to remain in force under the Human Medicines Regulations 2012.

Please send any comments or objections to bpcom@mhra.gov.uk 

The deadline for response is 27 February 2026.